Ultra-early clot aspiration after lysis with tissue plasminogen activator in a porcine model of intracerebral hemorrhage: edema reduction and blood-brain barrier protection
Kr. Wagner et al., Ultra-early clot aspiration after lysis with tissue plasminogen activator in a porcine model of intracerebral hemorrhage: edema reduction and blood-brain barrier protection, J NEUROSURG, 90(3), 1999, pp. 491-498
Object. Ultra-early hematoma evacuation (< 4 hours) after intracerebral hem
orrhage (ICB) may reduce mass effect and edema development and improve outc
ome. To test this hypothesis, the authors induced lobar hematomas in pigs.
Methods. The authors infused 2.5 mi of blood into the frontal cerebral whit
e matter in pigs weighing 8 to 10 kg. In the treatment group, clots were ly
sed with tissue plasminogen activator ([tPA], 0.3 mg) and aspirated at 3.5
hours after hematoma induction. Brains were frozen in situ at 24 hours post
-ICH and hematomal and perihematomal edema volumes were determined on coron
al sections by using computer-assisted morphometry.
Hematoma evacuation rapidly reduced elevated cerebral tissue pressure from
12.2 +/- 1.3 to 2.8 +/- 0.8 mm Hg. At 24 hours, prior clot removal markedly
reduced hematoma volumes (0.40 +/- 0.10 compared with 1.26 +/- 0.13 cm(3),
p < 0.005) and perihematomal edema volumes (0.28 +/- 0.05 compared with 1.
46 +/- 0.24 cm(3), p < 0.005), compared with unevacuated control lesions. F
urthermore, no Evans blue dye staining of perihematomal edematous white mat
ter was present in brains in which the hematomas had been evacuated, compar
ed with untreated controls.
Conclusions. Hematomas were quickly and easily aspirated after treatment wi
th tPA, resulting in significant reductions in mass effect. Hematoma aspira
tion after fibrinolysis with tPA enabled removal of the bulk of the hematom
a (> 70%), markedly reduced perihematomal edema, and prevented the developm
ent of vasogenic edema. These findings in a large-animal model of ICH provi
de support for clinical trials that include the use of fibrinolytic agents
and ultra-early stereotactically guided clot aspiration for treating ICH.